# Signaling Mechanisms and Vascular Function in Diabetes Mellitus

> **NCT00761852** · PHASE2,PHASE3 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ruboxistaurin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00761852
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2008-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761852, "Signaling Mechanisms and Vascular Function in Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00761852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*